Health Diagnostics Company Torus Biosystems Raises $25 Million

Aitechpark27 May, 2021Technology

New Funding to Support Development and Commercialization of Rapid, Molecular Point-of-Care Testing System Torus Biosystems, a company pioneering the future of infectious disease diagnostics, today announced the completion of a $25 million Series A financing. The round was led by Northpond Ventures, with participation from prior investors including David Walt, PhD, a professor at Harvard Medical School and Torus Bio cofounder and board observer. Adam Wieschhaus, PhD, CFA, director at Northpond Ventures, will also join the Torus board. Funding proceeds will be used to accelerate commercialization of a first-in-class syndromic testing solution designed for point-of-care use in ambulatory care settings.